Literature DB >> 22371394

CD4(+) type II NKT cells mediate ICOS and programmed death-1-dependent regulation of type 1 diabetes.

Nadir Kadri1, Eva Korpos, Shashank Gupta, Claire Briet, Linda Löfbom, Hideo Yagita, Agnes Lehuen, Christian Boitard, Dan Holmberg, Lydia Sorokin, Susanna L Cardell.   

Abstract

Type 1 diabetes (T1D) is a chronic autoimmune disease that results from T cell-mediated destruction of pancreatic β cells. CD1d-restricted NKT lymphocytes have the ability to regulate immunity, including autoimmunity. We previously demonstrated that CD1d-restricted type II NKT cells, which carry diverse TCRs, prevented T1D in the NOD mouse model for the human disease. In this study, we show that CD4(+) 24αβ type II NKT cells, but not CD4/CD8 double-negative NKT cells, were sufficient to downregulate diabetogenic CD4(+) BDC2.5 NOD T cells in adoptive transfer experiments. CD4(+) 24αβ NKT cells exhibited a memory phenotype including high ICOS expression, increased cytokine production, and limited display of NK cell markers, compared with double-negative 24αβ NKT cells. Blocking of ICOS or the programmed death-1/programmed death ligand 1 pathway was shown to abolish the regulation that occurred in the pancreas draining lymph nodes. To our knowledge, these results provide for the first time cellular and molecular information on how type II CD1d-restricted NKT cells regulate T1D.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22371394     DOI: 10.4049/jimmunol.1101390

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

Review 1.  Type II NKT cells: a distinct CD1d-restricted immune regulatory NKT cell subset.

Authors:  Suryasarathi Dasgupta; Vipin Kumar
Journal:  Immunogenetics       Date:  2016-07-12       Impact factor: 2.846

Review 2.  Different subsets of natural killer T cells may vary in their roles in health and disease.

Authors:  Vipin Kumar; Terry L Delovitch
Journal:  Immunology       Date:  2014-07       Impact factor: 7.397

Review 3.  The immunoregulatory role of type I and type II NKT cells in cancer and other diseases.

Authors:  Masaki Terabe; Jay A Berzofsky
Journal:  Cancer Immunol Immunother       Date:  2014-01-03       Impact factor: 6.968

4.  The adaptor protein SAP regulates type II NKT-cell development, cytokine production, and cytotoxicity against lymphoma.

Authors:  Xiufang Weng; Chia-Min Liao; Sreya Bagchi; Susanna L Cardell; Paul L Stein; Chyung-Ru Wang
Journal:  Eur J Immunol       Date:  2014-10-28       Impact factor: 5.532

Review 5.  Type II NKT Cells and Their Emerging Role in Health and Disease.

Authors:  Madhav V Dhodapkar; Vipin Kumar
Journal:  J Immunol       Date:  2017-02-01       Impact factor: 5.422

6.  Type II NKT-TFH cells against Gaucher lipids regulate B-cell immunity and inflammation.

Authors:  Shiny Nair; Chandra Sekhar Boddupalli; Rakesh Verma; Jun Liu; Ruhua Yang; Gregory M Pastores; Pramod K Mistry; Madhav V Dhodapkar
Journal:  Blood       Date:  2014-12-11       Impact factor: 22.113

Review 7.  Molecular basis of lipid antigen presentation by CD1d and recognition by natural killer T cells.

Authors:  Enrico Girardi; Dirk M Zajonc
Journal:  Immunol Rev       Date:  2012-11       Impact factor: 12.988

8.  NKT Cell Subsets Can Exert Opposing Effects in Autoimmunity, Tumor Surveillance and Inflammation.

Authors:  Rachael Viale; Randle Ware; Igor Maricic; Varun Chaturvedi; Vipin Kumar
Journal:  Curr Immunol Rev       Date:  2012-11-01

9.  Dendritic cells and anergic type I NKT cells play a crucial role in sulfatide-mediated immune regulation in experimental autoimmune encephalomyelitis.

Authors:  Igor Maricic; Ramesh Halder; Felix Bischof; Vipin Kumar
Journal:  J Immunol       Date:  2014-06-27       Impact factor: 5.422

Review 10.  Therapeutic manipulation of natural killer (NK) T cells in autoimmunity: are we close to reality?

Authors:  Y Simoni; J Diana; L Ghazarian; L Beaudoin; A Lehuen
Journal:  Clin Exp Immunol       Date:  2013-01       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.